Observational MRI Study for Intracranial Atherosclerotic Stenosis (ICAS)
This study is looking at people who have had a stroke caused by a narrowing of blood vessels in the brain (Intracranial Atherosclerotic Stenosis or ICAS). It's an add-on to another study called CAPTIVA, which is comparing different blood thinners like aspirin plus ticagrelor, clopidogrel, or rivaroxaban. This study uses extra MRI scans at the beginning and after 12 months to see if certain markers on the MRI can predict if someone will have another stroke. You could join if you are already in the CAPTIVA trial, had a recent stroke due to 70-99% narrowing of certain brain arteries, and can have an MRI. The goal is to find better ways to identify patients at risk and improve future treatments.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment for this study. It plans to enroll 300 participants.
- What's involved
- You would have an additional MRI scan at the start of the study and another one 12 months later.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months to measure the primary outcome.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
At a glance
Conditions
NCT05907629
Where you'd take part
This study runs at 28 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Baptist Medical Center Jacksonville
Jacksonville, Floridastudy coordinator listed
Recruiting
Barnes Jewish Hospital
St Louis, Missouristudy coordinator listed
Recruiting
Buffalo General Medical Center
Buffalo, New Yorkstudy coordinator listed
Recruiting
Carolinas Medical Center
Charlotte, North Carolinastudy coordinator listed
Not yet recruiting
Cleveland Clinic Akron General
Akron, Ohiostudy coordinator listed
Not yet recruiting
Cleveland Clinic Tradition Hospital
Port Saint Lucie, Floridastudy coordinator listed
Not yet recruiting
Covenant Medical Center
Lubbock, Texasstudy coordinator listed
Not yet recruiting
Duke University Hospital
Durham, North Carolinastudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David Liebeskind, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
- Sepideh Amin-Hanjani, MD · PRINCIPAL_INVESTIGATOR · University Hospitals
- Rano Chatterjee, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
- Adam de Havenon, MD, MS · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Establish ICAS hemodynamic and plaque MRI biomarkers as reliable predictors of recurrent ischemic stroke in the vascular territory of the index stroke.12 months
Recurrent ischemic stroke, defined as symptomatic infarct in the vascular territory of the index stroke artery. This outcome is centrally adjudicated in CAPTIVA using an American Heart Association definition of ischemic stroke